“CytoDyn will soon receive results from a precli
Post# of 157605
(Total Views: 705)
Posted On: 09/09/2024 6:49:15 PM
“CytoDyn will soon receive results from a preclinical study of leronlimab in a mouse model of MASH. That study is meant to clarify the correct dosing of leronlimab in the MASH setting and address the question of potential synergy with Resmetirom, the only currently approved therapy for the treatment of MASH.“
Anyone else looking forward to this? If the results are good this could mean a phase 3 combo with their company?
This could be a big deal.
Anyone else looking forward to this? If the results are good this could mean a phase 3 combo with their company?
This could be a big deal.
(11)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Federal Whistleblower
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf
Federal Whistleblower
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf